Breast Cancer | Topics

 
Fulvestrant/Palbociclib Combo Yields Anti-Tumor Activity But Did Not Improve PFS In HR-positive, ERBB2-Negative Advanced Breast Cancer
November 02, 2021

Patients with hormone receptor–positive, ERBB2-negative advanced breast cancer experienced significant anti-tumor activity when treated with fulvestrant and palbociclib but did not see an improvement in progression-free survival compared with letrozole and palbociclib .

Equivalent Toxicity, PROs Noted With Higher Radiation Dose Over Fewer Fractions After Breast Conserving Surgery
October 26, 2021

Patients who were treated with extreme hypofractionation after breast conserving surgery saw no increase in ill-treatment effects compared with those receiving moderate hypofractionation.

First Oral SERD Elacestrant Achieves Positive Findings in EMERALD Trial for ER+/HER2– Advanced or Metastatic Breast Cancer
October 21, 2021

Patients with estrogen receptor–positive, HER2-negative advanced or metastatic breast cancer experienced a progression-free survival benefit after being treated with elacestrant.

Biennial Mammography Screenings Reduce Breast Cancer Mortality Disparities in Black Populations
October 21, 2021

Investigators compared tradeoffs in breast cancer screening strategies in Black patients vs White patients.

Clinical Practice Recommendations Published For Immunotherapy to Treat Breast Cancer
October 16, 2021

The Society for Immunotherapy of Cancer published clinical practice guidelines for treating patients with breast cancer using immunotherapy.

FDA Approves Companion Diagnostic For Adjuvant Abemaciclib in High-Risk Early Breast Cancer
October 15, 2021

The FDA has given the Ki-67 IHC MIB-1 pharmDx assay a companion diagnostic approval for detecting Ki-67 expression in patients with high-risk early breast cancer who are being considered for treatment with abemaciclib.

FDA Approves Adjuvant Abemaciclib Plus ET for Resected High-Risk Early Breast Cancer
October 13, 2021

Based on a subgroup analysis from the monarchE trial, the FDA approved abemaciclib as adjuvant therapy in women with high-risk early breast cancer

Correlation Identified Between Financial Toxicity and Disparities in Psychosocial, Physical, and Mental Quality of Life in Breast Cancer
October 13, 2021

Investigators identified a correlation between financial toxicity significant differences in mental and physical quality of life, and patient satisfaction with breast reconstruction among patients with breast cancer.

Prognostic Value of Residual Disease Burden Appears Consistent in Early Breast Cancer Regardless of Disease Subtype
October 03, 2021

Patients with early breast cancer appear to have consistent prognostic value associated with residual cancer burden, regardless of disease subtype.